周二（9月9日）早盘，AH创新药再度异动。A股创新药龙头股领涨，百济神州大涨超6%，重仓创新药 的药ETF（562050）盘中续涨逾1%创上市新高！ 港股方面，荣昌生物一度暴拉逾15%创历史新高，乐普生物-B、君实生物大涨超7%，创新药纯度100% 的港股通创新药ETF（520880）开盘后快速探底回升，直线冲高逾1%，开盘不到30分钟成交额超2亿 元。 消息面上，荣昌生物最新宣布，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普 用于治疗干燥综合征的上市申请，已获国家药品监督管理局药品审评中心（CDE）正式受理，成为干燥 综合征领域全球首个申请上市的生物药。 值得关注的是，昨日港股通创新药ETF（520880）标的指数"提纯"修订生效，正式成为一只不含 CXO、纯度100%的创新药指数，当日近8200万元大举涌入，至此，520880连续5日获资金加码，金额 合计近1.8亿元。 与此同时，场外投资利器火线上新！港股通创新药ETF（520880）联接基金（A类：025220 / C类： 025221）今日起开放日常申赎，场外投资者也能一键投资纯正创新药。 提醒：近期市场波动可能较大，短期涨 ...

Group 1 - The innovative drug concept showed strong fluctuations in early trading on September 9, with Rongchang Bio rising over 18%, reaching a historical high [1] - Other companies such as Yipinhong, Baiji Shenzhou, Junshi Biosciences, XinNuoWei, and Rejing Bio also experienced gains [1]

（原标题：创新药概念股走高，荣昌生物涨超15%） 人民财讯9月9日电，创新药概念股走高，荣昌生物涨超15%，济民健康涨停，一品红涨超8%，百济神州、君实生物、金城医药跟涨。 ...

Core Viewpoint - The innovative drug concept is gaining momentum, with Rongchang Biopharmaceuticals experiencing a significant stock increase of over 15%, reaching a historical high, following the acceptance of its drug application for a novel treatment for Sjögren's syndrome [1] Company Summary - Rongchang Biopharmaceuticals announced that its self-developed innovative drug, a first-in-class BLyS/APRIL dual-target fusion protein named Tai Tasi Pu, has received formal acceptance from the National Medical Products Administration (NMPA) for its market application [1] - This drug application marks the first-ever submission for a biological drug in the Sjögren's syndrome field globally [1] Industry Summary - The innovative drug sector is experiencing a strong upward trend, with several companies such as Yipinhong, Baiji Shenzhou, Junshi Biosciences, Xin Nuo Wei, and Rejing Biopharmaceuticals also seeing stock price increases alongside Rongchang Biopharmaceuticals [1]

人民财讯9月9日电，9月9日，荣昌生物(688331)在公众号上发文宣布，公司自主研发的全球首创 BLyS/APRIL双靶点融合蛋白创新药泰它西普(商品名：泰爱)用于治疗干燥综合征的上市申请，已获国 家药品监督管理局药品审评中心(CDE)正式受理，成为干燥综合征领域全球首个申请上市的生物药。 ...

人民财讯9月9日电，2025年9月9日上午，荣昌生物A股、H股双双大涨。截至发稿时间，荣昌生物A股 涨超13%，股价突破百元大关，创出历史新高；H股大涨超11%，续创年内新高。 ...

Core Viewpoint - Rongchang Biopharma (09995) experienced a significant stock price increase of nearly 14%, with a year-to-date gain of 600% [1] Group 1: Stock Performance - As of the report, the stock price reached 110.2 HKD, with a trading volume of 494 million HKD [1] Group 2: Product Development - The company announced that its self-developed innovative drug, Tai'aisip (泰它西普), targeting both BLyS and APRIL, has received formal acceptance for market application from the National Medical Products Administration (NMPA) for the treatment of Sjogren's syndrome [1] - This marks the first application for a biological drug in the global market for Sjogren's syndrome, as there are currently no approved targeted therapies for this condition [1] Group 3: Regulatory Approvals - Tai'aisip has been granted Fast Track designation by the U.S. FDA and is approved to conduct Phase III clinical trials in the U.S. [1] - The drug has also received approvals for treating systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) in China [1]

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-042 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 09 月 16 日(星期二)15:00-17:00 会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 09 月 16 日（星期二）15:00-17:00 荣昌生物制药（烟台）股份有限公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 09 ...

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Group 1 - The article emphasizes that macroeconomic factors and market trends have limited guidance for individual stock investments, except during critical turning points [1] - The upcoming Federal Reserve interest rate cuts and global geopolitical changes are identified as a key turning point, particularly benefiting the Hong Kong stock market [1] - The Hang Seng Index is expected to reach historical highs in the next three to five years, driven by the technology and innovative pharmaceutical sectors [1] Group 2 - Hong Kong stocks are highlighted as a mature market with significant growth potential, featuring competitive high-tech and innovative pharmaceutical companies such as Tencent, Alibaba, SMIC, Xiaomi, and others [1] - The decline in interest rates in Hong Kong, following the U.S. dollar's rate cuts, is anticipated to attract international capital back to the Hong Kong stock market [1] - The brokerage sector in Hong Kong is expected to benefit directly from the rising stock indices, making brokerage stocks worth noting in the short term [1]